Health
The Week
Johnson & Johnson announced the start of phase three of its coronavirus vaccine trial this week, citing "positive interim results" from earlier stages of its study. Those were published Friday, and they were indeed promising.The pharmaceutical giant reported that 99 percent of the participants between the ages of 18 and 55 in early-to-mid stage clinical trials developed neutralizing antibodies against the novel virus. The analysis also found that most of the side effects associated with the vaccine were mild and resolved within a matter of days.It wasn't clear, however, whether participants over 65 were well-protected since immune response results were available for only 15 people in that demographic.